What Dolphin 3% Treats: Main Uses and Benefits

The Dolphin 3% Topical Solution, a high-concentration Diclofenac formulation, is applied in addressing certain pathological skin conditions. Its therapeutic scope is commonly used to help with managing sun-related damage and the resulting skin changes, primarily concerning the management of Actinic Keratosis (AK).

---

Topical Treatment for Actinic Keratosis (AK)

This solution is generally used for the localized management of Actinic Keratosis, which manifests as rough, scaly, and crusty patches on sun-exposed skin. These lesions are considered precancerous skin changes resulting from long-term ultraviolet (UV) exposure. This 3% concentration is formulated for this purpose. The treatment is used for managing the scaly growths and rough patches, relevant in clinical settings involving sun-exposed areas of the body and adult patient groups.

Reduction of Lesions and Associated Risk

In managing the symptomatic manifestations, the treatment may assist with resolving the scaly growths and is considered relevant for easing the long-term risk of the lesions becoming a more severe skin condition. This supports the patient during difficult episodes by easing distress and is commonly used to help with managing the overall burden of skin damage pathology.

---

Quick Fact: Relevant for Managing Persistent Skin Manifestations

Regulatory References

1. DailyMed listing published by the NIH

Eligibility Map: Who Can and Cannot Use Dolphin 3% — Official Regulatory Information

This section documents the official population eligibility and non-eligibility for Dolphin 3% (Diclofenac 3% Topical Solution), based strictly on government-approved regulatory documents.

Category	Official Regulatory Status
Populations for whom use is allowed (as stated in label):	Adults (typically 18 years of age and older) for the labeled indication.
Populations for whom use is contraindicated:	Individuals with a known hypersensitivity to diclofenac or any NSAID (e.g., aspirin), or those who have had allergic-type reactions to them.
Age-related eligibility rules:	Pediatric Use: Safety and efficacy have not been established for children and adolescents. Geriatric Use: Generally allowed, but caution is warranted due to the increased potential for age-related cardiac or renal issues.
Pregnancy and lactation eligibility status (if explicitly documented):	Contraindicated in the third trimester of pregnancy. Use between 20 and 30 weeks is limited. During lactation, use is generally acceptable but the product must not be applied to the breasts.
Eligibility-related restrictions:	Prohibited for use in the setting of Coronary Artery Bypass Graft (CABG) surgery. Prohibited for application to open wounds or otherwise damaged or non-intact skin.
Condition-specific eligibility rules:	Use with caution in patients with active gastrointestinal ulceration/bleeding, severe renal impairment, or severe heart failure (avoid unless benefits clearly outweigh risk).

---

Resulting Eligibility Structure

Official eligibility statements:

• The use of Dolphin 3% is contraindicated in patients with a history of allergic-type reactions to aspirin or other NSAIDs.
• The medicine is contraindicated in women in the third trimester of pregnancy.
• Safety and efficacy have not been established for use in the pediatric population.

Connection to the overall eligibility profile Official regulatory documents define eligibility by strictly setting boundaries for who may use this medicine based on physiological status, age, and pre-existing conditions. These boundaries include absolute exclusions (contraindications), such as known NSAID allergy or late-stage pregnancy, and conditional restrictions (use with caution or avoidance) for patients with specific systemic conditions like severe cardiac or renal impairment, reflecting the potential for minor systemic exposure.

The interaction profile for Dolphin 3% (Diclofenac Topical Solution) is officially documented based on the established pharmacological class effects of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), despite the low systemic absorption from topical application. These interactions are classified as those creating additive risk, those modifying the exposure of other drugs, and procedural co-administration restrictions. The risk for systemic adverse effects, such as gastrointestinal bleeding, is officially documented as increased when Dolphin 3% is used with oral NSAIDs or aspirin.

Interacting Substance/Class	Documented Interaction Outcome
Oral NSAIDs / Aspirin	Increased NSAID adverse effects (additive systemic exposure).
Anticoagulants (e.g., Warfarin)	Increased risk of serious gastrointestinal bleeding.
ACE Inhibitors / Diuretics	May diminish the antihypertensive or natriuretic effect.
Lithium / Methotrexate	Potential for increased plasma concentration and toxicity of co-administered drug.

These systemic interaction risks are officially noted as being heightened in populations with impaired renal function. A key procedural constraint exists for the local application site: the safety and efficacy of using sunscreens, cosmetics, or other topical medications simultaneously on the treated area is unknown, and co-administration is officially not recommended according to regulatory labeling. The profile is defined by these specific additive risks and administration separation requirements.

Enzymatic Inhibition of Prostaglandin Synthesis

The action of Diclofenac (Dolphin 3%) is characterized by pharmacodynamic modulation of inflammatory pathways. The core mechanism involves the competitive inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. COX-2 expression is elevated in inflammatory states; its inhibition blocks the conversion of Arachidonic Acid into prostaglandins, which are powerful chemical mediators. By reducing the local concentration of these synthesized prostanoids, the drug functionally interferes with a key step in the Arachidonic Acid cascade.

Modulation of Local Inflammatory and Nociceptive Signaling

The reduction in prostaglandins, particularly PGE2, results in two principal physiological consequences within the periphery. First, it diminishes the signaling that increases vascular permeability, leading to a consequent reduction in localized fluid extravasation. Second, PGE2 normally sensitizes peripheral nerve endings (nociceptors); thus, the drop in PGE2 results in decreased peripheral nociceptor hypersensitivity, which modulates the propagation of nociceptive signals. The mechanism is functionally peripheral.

How to Use Dolphin 3% (Diclofenac 3% Topical Gel)

---

The usage of Dolphin 3% follows a precise, standardized protocol for the cutaneous use of its 3% Diclofenac Sodium formulation, intended for a specific duration of therapy.

Standard Dosing and Administration

The solution is administered topically to the affected lesion areas on the skin. The standard dosage is an amount of gel sufficient to adequately cover the lesion, typically measured as 0.5 grams (approximately a pea-sized amount) for a 5 imes 5 cm site. This application must be repeated twice daily, once in the morning and once in the evening.

Administration Component	Guideline
Route of Administration	Cutaneous (Topical)
Standard Single Dose	0.5 grams of gel per 25 cm^2 area
Maximum Daily Dose	Must not exceed 8 grams of gel total
Dosing Frequency	Twice daily (e.g., morning and evening)

Treatment Duration and Procedural Rules

The typical course of therapy ranges from 60 to 90 days. Following the final application, the full therapeutic effect may not be apparent for up to 30 days.

Proper application requires the gel to be gently rubbed into clean, dry, intact skin. Standard procedure involves washing hands thoroughly immediately after each use, unless the hands themselves are the site of treatment. The area of application must not be covered with an airtight occlusive dressing, and exposure to natural or artificial sunlight should be avoided throughout the treatment period.

Research evidence / Overview of studies for Dolphin 3%

Research Evidence for Actinic Keratosis

The Diclofenac 3% solution was studied for the localized management of Actinic Keratosis (AK). The evidence base consists of multiple formal clinical studies, most notably Randomized Controlled Trials (RCTs). These research designs are used in research exploring how symptoms change over time compared to an inactive base.

The studies examined outcomes related to physical discomfort and the study outcomes related to the status of the rough, scaly lesions associated with AK. Findings describe patterns related to the clearance of these lesions in adult study populations, and the evidence is part of the research landscape concerning symptom patterns in this chronic skin condition.

---

Study Design and Comparisons

In the key studies that was evaluated in regulatory review, the active Diclofenac 3% solution was compared against its inactive gel vehicle (a placebo). Trials were conducted during defined time intervals where study participants were assigned to the solution over a period of 60 to 90 days.

The primary endpoint, which measured the proportion of patients with complete clearance, was monitored one month after the treatment course had finished. Other studies examined the proportion of patients who achieved a partial clearance of at least 75% of their lesions. In trials where the solution was compared against other active topical AK therapies, findings were sometimes mixed regarding the outcomes measured.

---

Long-Term Follow-up and Durability of Response

Studies monitored the status of the treated skin after the initial treatment and follow-up phase. This long-term research examined how lesions evolved in the observed populations for up to one year. Further research was observed in studies examining the incidence of lesions advancing to more serious stages for periods extending up to two or three years. This evidence is relevant in trials assessing outcomes reflecting daily functioning, though long-term effects are not fully established beyond these follow-up periods.

---

Research Gaps and Remaining Uncertainties

Comparative evidence is lacking for the solution against the complete range of all available topical treatments for Actinic Keratosis. Furthermore, follow-up durations were limited in certain subgroup studies, and the evidence quality varies across studies, meaning the data provide limited insight into broad conclusions about the treatment in all possible research contexts. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Common questions about Dolphin 3% (FAQ)

Q: Can I take this medication with alcohol?

Regulatory documents address potential interactions between this medicine and alcohol. Official product information states whether studies have been conducted or if warnings apply to concomitant use. This information is included as a specific warning or precaution in the official labeling.

Q: Does this medication make you sleepy or affect driving?

The official product information addresses the potential for effects on the central nervous system (CNS). Regulatory documents indicate if side effects like drowsiness, dizziness, or sedation are possible. The official labeling will include warnings about operating machinery or driving if these side effects are known.

Q: What is the correct way to store this medicine?

The official instructions specify the required storage conditions to maintain the quality and effectiveness of the medicine. This includes the recommended temperature range and precautions against moisture or light. Refer to the storage information provided in the official patient leaflet.

Q: Can children under 12 years old use this?

The official regulatory documents define the approved age range for the use of Dolphin 3%. The product information will state whether the medication's safety and effectiveness have been established for children under 12 years old, or if its use has not been approved or adequately studied in this age group.

Q: What should I do if I miss a dose?

The patient information leaflet provides explicit instructions on how to handle a missed dose. This guidance will typically state whether taking the dose as soon as it is remembered is recommended, or if the missed dose should be skipped.

Q: Are there any foods or dietary supplements I should avoid?

Regulatory information lists known interactions, which includes specific foods, beverages (like grapefruit juice), or dietary supplements. This information details which items might affect how the medicine works or increase the risk of side effects. This information is detailed within the official documents.

Q: Can I take this if I am pregnant or breastfeeding?

The official product information contains statements regarding the use of this medicine during pregnancy and breastfeeding. It provides detailed information on known risks, the availability of data, and whether the medicine or its byproducts are expected to pass into human milk.

The Diclofenac Topical Solution 3% (Dolphin 3%) must be stored and discarded according to regulatory requirements to ensure product quality and safety.

Storage Conditions

The solution must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It must be stored in a closed container and kept out of the sight and reach of children and pets. Mandatorily, the product must be kept from freezing and protected from heat, moisture, and direct light. Use of the medicine is prohibited after the labeled expiration date.

Disposal Instructions

Unused or expired solution must be disposed of in accordance with local regulations. The preferred method is using a drug take-back program. If this is unavailable, the solution should not be flushed into the wastewater. Instead, mix the product with an undesirable substance (such as dirt or coffee grounds), seal it in a container, and place it in the household trash. Personal information must be scratched off the original packaging before disposal.